Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT)

Response to Office Action Dated: March 08, 2010

Page 2 of 9

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A substituted p-diaminobenzene derivative of the general formula

wherein:

s is 0 or 1;

U is O, S, SO₂, SONR¹¹, or CONR¹¹; wherein:

 R^{11} is hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, or C_{3-8} -cycloalk(en)yl- C_1 . 6-alk(en/yn)yl; or

R² and R¹¹ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms;

q is 0 or 1;

X is CO or SO₂; with the proviso that q is 0 when X is SO₂;

Z is O or S;

 $R^{1} \text{ is hydrogen, } C_{1-6}\text{-alk}(\text{en/yn})\text{yl, } C_{3-8}\text{-cycloalk}(\text{en})\text{yl, } C_{3-8}\text{-cycloalk}(\text{en})\text{yl-}C_{1-6}\text{-alk}(\text{en/yn})\text{yl, hydroxy-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl, hydroxy-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl, hydroxy-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl, halo-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl, halo-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl, halo-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl, cyano-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl or cyano-}C_{3-8}\text{-cycloalk}(\text{en})\text{yl-}C_{1-6}\text{-alk}(\text{en/yn})\text{yl;}$

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Office Action Dated: March 08, 2010 Page 3 of 9

 $R^2 \text{ is hydrogen, } C_{1\text{-}6}\text{-}alk(en/yn)yl, C_{3\text{-}8}\text{-}cycloalk(en)yl, C_{3\text{-}8}\text{-}cycloalk(en)yl-C_{1\text{-}6}\text{-}alk(en/yn)yl, Ar. Ar-C_{1\text{-}6}\text{-}alk(en/yn)yl, Ar-C_{3\text{-}8}\text{-}cycloalk(en)yl, Ar-C_{3\text{-}8}\text{-}cycloalk(en)yl-C_{1\text{-}6}\text{-}alk(en/yn)yl, hydroxy-C_{3\text{-}8}\text{-}cycloalk(en)yl, hydroxy-C_{3\text{-}8}\text{-}cycloalk(en)yl, hydroxy-C_{3\text{-}8}\text{-}cycloalk(en)yl, halo-C_{3\text{-}8}\text{-}cycloalk(en)yl, halo-C_{3\text{-}8}\text{-}cycloalk(en)yl, halo-C_{3\text{-}8}\text{-}cycloalk(en)yl, cyano-C_{3\text{-}8}\text{-}cycloalk(en)yl, cyano-C_{3\text{-}8}\text{-}cycloalk(en)yl, NR^{10}R^{10}\text{-}C_{3\text{-}8}\text{-}cycloalk(en)yl, NR^{10}R^{10}\text{-}C_{3\text{-}8}\text{-}cycloalk(en)yl, NR^{10}R^{10}\text{-}C_{3\text{-}8}\text{-}cycloalk(en)yl, wherein:}$

 R^{10} and R^{10} are each independently hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl, hydroxy- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, cyano- C_{3-8} -cycloalk(en)yl or cyano- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or

R¹⁰ and R¹⁰ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms, with the proviso that:

when R² is halogen or cyano, then s is 0; and
when s is 1 and R² is a hydrogen atom or acyl, then U is O or S;

 $R^3 \text{ is } C_{1-6}\text{-alk}(\text{en/yn})yl, C_{3-8}\text{-cycloalk}(\text{en})yl, \text{ heterocycloalk}(\text{en})yl, C_{3-8}\text{-cycloalk}(\text{en})yl-C_{1-6}\text{-alk}(\text{en/yn})yl, C_{1-6}\text{-alk}(\text{en/yn})yl-C_{3-8}\text{-cycloalk}(\text{en})yl, C_{1-6}\text{-alk}(\text{en/yn})yl-\text{heterocycloalk}(\text{en})yl, \\ heterocycloalk}(\text{en})yl-C_{1-6}\text{-alk}(\text{en/yn})yl, C_{1-6}\text{-alk}(\text{en/yn})yloxy-C_{1-6}\text{-alk}(\text{en/yn})yl, C_{3-8}\text{-cycloalk}(\text{en})yl, C_{1-6}\text{-alk}(\text{en/yn})yloxy-C_{3-8}\text{-cycloalk}(\text{en})yl, C_{1-6}\text{-alk}(\text{en/yn})yloxy-\text{carbonyl-}C_{1-6}\text{-alk}(\text{en/yn})yl, C_{3-8}\text{-cycloalk}(\text{en})yl-C_{1-6}\text{-alk}(\text{en/yn})yloxy-\text{carbonyl-}C_{1-6}\text{-alk}(\text{en/yn})yl, C_{3-8}\text{-cycloalk}(\text{en})yl-C_{1-6}\text{-alk}(\text{en/yn})yl, hydroxy-C_{3-8}\text{-cycloalk}(\text{en})yl, hydroxy-C_{1-6}\text{-alk}(\text{en/yn})yl, hydroxy-C_{1-6}\text{-alk}(\text{en/yn})yl-C_{1-6}\text{-alk}(\text{en/yn})yl, hydroxy-C_{1-6}\text{-alk}(\text{en/yn})yl-C_{3-8}\text{-cycloalk}(\text{en})yl, hydroxy-C_{1-6}\text{-alk}(\text{en/yn})yl-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, halo-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl, cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-alk}(\text{en/yn})yl-cyano-C_{1-6}\text{-a$

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT)

Response to Office Action Dated: March 08, 2010

Page 4 of 9

alk(en/yn)yl, cyano- C_{3-8} -cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl- C_{3-8} -cycloalk(en)yl, cyano- C_{1-6} -alk(en/yn)yl-heterocycloalk(en)yl, acyl- C_{3-8} -cycloalk(en)yl, acyl-heterocycloalk(en)yl, acyl- C_{3-8} -cycloalk(en)yl, acyl- C_{3-8} -cycloalk(en)yl, acyl- C_{1-6} -alk(en/yn)yl- C_{3-8} -cycloalk(en)yl, acyl- C_{1-6} -alk(en/yn)yl-heterocycloalk(en)yl, $NR^{12}R^{12}$, optionally substituted $NR^{12}R^{12}$ - C_{1-6} -alk(en/yn)yl, optionally substituted $NR^{12}R^{12}$ - C_{3-8} -alk(en/yn)yl, or optionally substituted $NR^{12}R^{12}$ - C_{3-8} -alk(en/yn)yl, wherein:

 $R^{12} \text{ and } R^{12} \text{ are each independently hydrogen, } C_{1.6}\text{-alk(en/yn)yl, } C_{3.8}\text{-cycloalk(en)yl-} C_{1.6}\text{-alk(en/yn)yl, } Ar, Ar-C_{1-6}\text{-alk(en/yn)yl, } Ar-C_{3.8}\text{-cycloalk(en)yl-} C_{1.6}\text{-alk(en/yn)yl, } Ar-heterocycloalk(en)yl, } Ar-oxy-C_{1.6}\text{-alk(en/yn)yl, } Ar-oxy-C_{3.8}\text{-cycloalk(en)yl, } Ar-oxy-C_{3.8}\text{-cycloalk(en)yl-} C_{1.6}\text{-alk(en/yn)yl, } Ar-oxy-heterocycloalk(en)yl, } Ar-oxy-C_{3.8}\text{-cycloalk(en)yl, } Ar-oxy-C_{3.8}\text{-cy$

R¹² and R¹² taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms; with the proviso that when R³ is NR¹²R¹² then q is 0; and

Y is a group of formula XXXXI:

wherein:

" represents a bond attaching the group represented by Y to the carbon atom;
V is C or CH; and

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT)

Response to Office Action Dated: March 08, 2010

Page 5 of 9

k is 0, 1, 2 or 3; and

each R^5 is independently C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk (en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar, Ar- C_{1-6} -alk(en/yn)yl, Ar- C_{3-8} -cycloalk(en)yl, Ar- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar-oxy- C_{3-8} -cycloalk(en)yl, C_{1-6} -alk(en/yn)yl-heterocycloalk(en)yl, Ar-oxy- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, acyl, C_{1-6} -alk(en/yn)yloxy, C_{3-8} -cycloalk(en)yloxy, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)yloxy-carbonyl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{3-8} -cycloalk(en)yl, halo- C_{3-8} -cycloalk(en)yl, cyano- C_{3-8} -cycloalk(en)yl, cyano- C_{3-8} -cycloalk(en)yl, cyano- C_{3-8} -cycloalk(en)yl, cyano- C_{3-8} -cycloalk(en)yl, C_{1-6} -alk(en/yn)yl, C_{1-

two adjacent R⁵ groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms; wherein:

 R^6 and $R^{6'}$ are each independently hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl or Ar;

 R^7 and R^7 are each independently hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar, heterocycloalk(en)yl- C_{1-6} -alk(en/yn)yl, heterocycloalk(en)yl- C_{3-8} -cycloalk(en)yl- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, heterocycloalk(en)yl-Ar or acyl; or

R⁷ and R⁷ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; and

 R^8 is hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar or -NR 9 R 9 ; wherein:

 $R^9 \ and \ R^{9^{\cdot}} \ are each independently \ hydrogen, \ C_{1-6} - alk(en/yn)yl, \ C_{3-8} - cycloalk(en)yl-C_{1-6} - alk(en/yn)yl;$

or salts thereof.

Claim 2 (previously presented): The compound according to claim 1, wherein R^1 is C_{1-6} -alk(en/yn)yl or a hydrogen atom.

Claim 3 (previously presented): The compound according to claim 1, wherein s is 0.

Claim 4 (previously presented): The compound according to claim 1, wherein s is 1.

Claim 5 (previously presented): The compound according to claim 4, wherein U is an oxygen atom.

Claim 6 (previously presented): The compound according to claim 1, wherein R^2 is hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, Ar, Ar- C_{1-6} -alk(en/yn)yl, halogen, halo- C_{1-6} -alk(en/yn)yl or cyano; with the provisos that when R^2 is halogen or cyano, then s is 0; and when s is 1 and R^2 is a hydrogen atom, then U is O or S.

Claim 7 (previously presented): The compound according to claim 1, wherein Z is an oxygen atom.

Claim 8 (previously presented): The compound according to claim 1, wherein Z is a sulfur atom.

Claim 9 (previously presented): The compound according to claim 1, wherein q is 0.

Claim 10 (previously presented): The compound according to claim 1, wherein q is 1.

Claim 11 (previously presented): The compound according to claim 1, wherein X is CO.

Claim 12 (previously presented): The compound according to claim 1, wherein R^3 is C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, heterocycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar-oxy- C_{1-6} -alk(en/yn)yl, Ar- C_{1-6} -alk(en/yn)yl, Ar-oxy- C_{1-6} -alk(en/yn)yl, Ar- C_{1-6} -alk(en/yn)yloxy- C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yl, NR¹²R¹², optionally substituted NR¹²R¹²- C_{1-6} -alk(en/yn)yl, or optionally substituted NR¹²R¹²- C_{3-8} -cycloalk(en)yl.

Claim 13 (previously presented): The compound according to claim 12, wherein R^{12} and $R^{12'}$ are each independently hydrogen, C_{1-6} -alk(en/yn)yl or Ar.

Claims 14-20 (cancelled).

Claim 21 (previously presented): The compound according to claim 1, wherein V is CH.

Claims 22-24 (cancelled).

Claim 25 (previously presented): The compound according to claim 1, wherein each R^5 is independently C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yl-heterocycloalk(en)yl, Ar, C_{1-6} -

alk(en/yn)yloxy, Ar-oxy, C₁₋₆-alk(en/yn)yloxy-carbonyl, halogen, halo-C₁₋₆-alk(en/yn)yl, NR⁷R⁷, S-R⁸ or SO₂R⁸; or two adjacent R⁵ groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms.

Claim 26 (previously presented): The compound according to claim 25, wherein both R^7 and R^7 are C_{1-6} -alk(en/yn)yl.

Claim 27 (previously presented): The compound according to claim 25, wherein R^8 is C_{1-6} -alk(en/yn)yl or Ar.

Claim 28 (previously presented) The compound according to claim 1, wherein the compound is:

- 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-p-tolyloxypyridin-3-ylmethyl)-amino]-phenyl}-acetamide;
- 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-acetamide;
- 3,3-Dimethyl-N-{2-methyl-4-[(6-p-tolyloxypyridin-3-ylmethyl)-amino]-phenyl}-butyramide;
- 3,3-Dimethyl-N-{2-methyl-4-[(6-trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-butyramide;

N-(4-{[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-amino}-2-methylphenyl)-2-(4-fluorophenyl)-acetamide,

N-{4-[(6-Chloropyridin-3-ylmethyl)-amino]-2-methylphenyl}-2-(4-fluorophenyl)-acetamide; or 2,2-Dimethyl-N-{2-methyl-4-[(6-phenoxypyridin-3-ylmethyl)-amino]-phenyl}-proprionamide; or a salt thereof.

Claim 29 (previously presented) A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound according to claim 1.

Claims 30-45 (cancelled).